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Hepatocellular carcinoma (HCC) is one of the most lethal cancers, ranking third among all cancer-related 
mortalities worldwide. Recent studies have shown that hundreds of microRNAs (miRNAs) were deregulated in 
human HCC, however their biological functions during hepatocarcinogenesis are incompletely understood. In 
our recent study, we found several miRNAs were upregulated in HCCs from patients and a transgenic mouse 
model. Using human hepatoma cells expressing individual miRNAs, we tested pro-tumorigenic function of the 
overexpressed miRNAs. Even though biological functions in the development of HCC are not precisely known, 
some miRNAs can be potentially used as a diagnostic or prognostic serum marker for HCC. In our recent study, 
we identified several miRNAs that were specifically upregulated in patient sera with an early and/or advanced 
HCC. 
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Hepatocellular carcinoma (HCC) is one of the most lethal 
cancers, accounting for approximately a half million deaths 
worldwide annually [1, 2]. Treatment modalities developed for 
HCC offer mostly limited success and tumors recur in 
approximately 70% of patients within 5 years. Understanding 
the molecular mechanism underlying the pathogenesis of 
HCC would be highly important in developing effective 
target therapies for this deadly disease [3, 4]. Further, there is 
an urgent need for molecular markers for an early diagnosis 
of HCC with a minimal invasiveness [5].  
microRNAs (miRNAs) are 19~23 nucleotide-long 
non-coding RNA molecules that suppress gene expression 
via post-transcriptional regulation [6, 7]. Recent microarray 
studies have shown that hundreds of miRNAs were 
upregulated in human HCC [8, 9]. Although the microarray 
data are informative in various aspects, it is hard to know 
biological functions of the upregulated miRNAs in 
hepatocarcinogenesis. For example, of the deregulated 
miRNAs, some might play a major role in 
hepatocarcinogenesis while others are simply bystanders. For 
the precise determination of carcinogenic roles of miRNAs, 
functional tests of the miRNAs are required in HCC cells.  
From a quantitative RT-PCR, we identified several 
miRNAs that were significantly upregulated both in human 
and murine HCCs, such as miR-17-5p, miR-25, miR-155-5p, 
miR-181b-1, and miR-221. Using HCCs from both species 
allowed us to identify the miRNAs that were consistently 
upregulated in HCCs regardless of hepatitis B virus 
(HBV)-infection or the presence of fibrosis because human 
HCC tissues used in our study were from patients with HBV 
infection and hepatic fibrosis while the murine HCC model 
had no apparent hepatic fibrosis or HBV infection. To study 
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the role of the overexpressed miRNAs in HCCs, we 
generated human hepatoma cells stably expressing the 
individual miRNAs [10]. The genomic region encoding each 
miRNA was amplified by PCR and subsequently located 
right after the enhanced green fluorescent protein (EGFP) 
cDNA under the cytomegalovirus (CMV) promoter, allowing 
expression of miRNAs to be monitored via fluorescence 
imaging of EGFP (Figure 1). Placing the miRNA genes 
under the CMV promoter also allows the genes to be 
transcribed by PolII, the RNA polymerase that transcribes 
endogenous miRNA genes. Furthermore, the genetic loci of 
miRNAs were amplified using forward and reverse primers 
binding to several hundred base pairs up- and downstream of 
pre-miRNA locations. The transcripts from the 
miRNA-expression vectors are, therefore, expected to 
undergo the processes by RNAse III enzymes. Thus, 
miRNAs produced from the expression vectors are expected 
to have undergone the processes of transcription and 
biogenesis of endogenous miRNAs.   
Using stable HCC cell lines expressing miR-17-5p, 
miR-21-5p, or miR-221, we investigated proliferation and 
migration capabilities of cancer cells overexpressing each 
miRNA. Hepatoma cells expressing miR-221 showed 
increased cellular proliferation based on an MTT assay, 
while those expressing miR-17-5p exhibited an increased 
capability of migration determined by a wound-healing assay. 
Thus, overexpression of the miRNAs during 
hepatocarcinogenesis will likely increase the tumorigenic 
potential of neoplastic cells. Although numerous miRNAs 
are overexpressed in HCC, their biological functions during 
hepatocarcinogenesis remain largely unknown. 
Understanding the precise roles of individual miRNAs will 
expand our knowledge on the genetic mechanisms 
underlying HCC, leading to a better strategy for molecular 
targeted therapy.  
Some miRNAs that were upregulated in HCCs can be 
potentially used as a serum biomarker for diagnosis or 
prognosis of HCC [11, 12]. In our pilot study, we have found 
that several miRNAs including miR-25 were upregulated in 
sera from HCC patients regardless of the stages of cancer 
while miRNAs such as miR-222 were upregulated only in 
sera from patients with an advanced HCC (Figure 2). With 
the increasing knowledge on miRNA biology, the potential 
application of miRNAs to cancer biology will likely broaden 
in the future. 
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Figure 1. Construction of plasmids encoding pri-miRNAs. PCR was performed using human 
genomic DNA as a template to amplify the gene encoding each miRNA. Forward and reverse 
primers bind to locations 200–300 bp up- and downstream of pre-miRNA positions such that miRNA 
can be generated through the endogenous miRNA biogenesis pathway. The amplified PCR products 
were placed right after cDNA encoding enhanced green fluorescent protein (EGFP) under the CMV 
promoter. 
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Figure 2. Expression levels of serum miRNAs in normal healthy control and patients 
with viral hepatitis (HBV), early HCC, or advanced HCC. miRNAs were harvested from 
serum and used for a quantitative RT-PCR. Note that miR-25 showed upregulation in both 
early and advanced HCC patients while miR-222 was elevated only in patients with an 
advanced HCC. 
 
